Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a rare terminal neurodegenerative disease defined by the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction. ALS is the most common of the motor neuron diseases. ALS often presents with gradual muscle stiffness, twitches, weakness, and wasting. Motor neuron loss typically continues until the ability to eat, speak, move, and breathe without mechanical support is lost. At least 50% of people with ALS experience significant changes in thinking and behavior, with 15% of individuals going on to develop frontotemporal dementia. An ALS diagnosis is made based on a person's signs and symptoms, with additional testing conducted to rule out other potential causes. Depending on which areas of the body are affected first, ALS may be classified as limb-onset (beginning with weakness in the arms or legs) or bulbar-onset (beginning with difficulty in speaking or swallowing). Respiratory onset occurs in approximately 1–3% of cases. Most cases of ALS (about 90–95%) have no known cause and are known as sporadic ALS. Genetic, autoimmune, and environmental factors are believed to be involved in the onset of ALS. Approximately 5–10% of ALS cases have a known genetic cause and are often linked to a family history of ALS; such cases are known as familial ALS or hereditary ALS. Mutations in the C9orf72 gene are the most common known genetic cause of familial ALS and are also found in a subset of sporadic cases. Four disease-linked genes are responsible for approximately half of all genetic cases. There is no known cure for ALS. The goal of treatment is to slow the disease progression and improve symptoms. FDA-approved treatments that slow the progression of ALS include riluzole and edaravone. Non-invasive ventilation may result in both improved quality and length of life. Mechanical ventilation can prolong survival but does not stop disease progression. A feeding tube may help maintain weight and nutrition. Death is usually caused by respiratory failure. The disease can affect people of any age, but usually starts around the age of 60. The average survival from onset to death is two to four years, though this can vary; about 10% of those affected survive longer than ten years. Descriptions of the disease date back to at least 1824 by Charles Bell. In 1869, the connection between the symptoms and the underlying neurological problems was first described by French neurologist Jean-Martin Charcot, who in 1874 began using the term amyotrophic lateral sclerosis.
Classification ALS is a motor neuron disease, which are a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. Related motor neuron diseases, sometimes characterized as ALS variants rather than distinct entities, include primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy, pseudobulbar palsy, and monomelic amyotrophy (MMA). As a disease, ALS may be classified in several different ways: by which part of the motor neurons is affected; by the parts of the body first affected; whether it is genetic; and by the age at which it started. Each individual diagnosed with the condition will sit at a unique place at the intersection of these complex and overlapping subtypes, which presents a challenge to diagnosis, understanding, and prognosis.
Subtypes of disease
ALS can be classified by the types of motor neurons that are affected. To successfully control any voluntary muscle in the body, a signal must be sent from the motor cortex in the brain down the upper motor neuron as it travels down the spinal cord. There, it connects via a synapse to the lower motor neuron, which connects to the muscle itself. Damage to either the upper or lower motor neuron, as it makes its way from the brain to the muscle, causes different types of symptoms. Damage to the upper motor neuron typically causes spasticity including stiffness and increased tendon reflexes or clonus, while damage to the lower motor neuron typically causes weakness, muscle atrophy, and fasciculations. Classical or classic ALS involves degeneration to both the upper motor neurons in the brain and the lower motor neurons in the spinal cord. Primary lateral sclerosis (PLS) involves degeneration of primarily the upper motor neurons, and progressive muscular atrophy (PMA) involves the lower motor neurons primarily. There is debate over whether PLS and PMA are separate diseases or variants of ALS.
Classical ALS accounts for about 70% of all cases of ALS and can be subdivided into cases where symptoms first appear, as these are usually focused on one region of the body at initial presentation before later spread. Limb-onset ALS (also known as spinal-onset) and bulbar-onset ALS. Limb-onset ALS begins with weakness in the hands, arms, feet, and/or legs and accounts for about two-thirds of all classical ALS cases. Bulbar-onset ALS begins with weakness in the muscles of speech, chewing, and swallowing and accounts for about 25% of classical ALS cases. A rarer type of classical ALS affecting about 3% of patients is respiratory-onset, in which the initial symptoms are difficulty breathing (dyspnea) upon exertion, at rest, or while lying flat (orthopnea). Primary lateral sclerosis (PLS) accounts for about 5% of all ALS cases and only affects the upper motor neurons in the arms, legs, and bulbar region. However, more than 75% of people with apparent PLS go on to later develop lower motor neuron signs within four years of symptom onset, meaning that a definitive diagnosis of PLS cannot be made until several years have passed. PLS has a better prognosis than classical ALS, as it progresses more slowly, results in less functional decline, does not affect the ability to breathe, and causes less severe weight loss than classical ALS. Progressive muscular atrophy (PMA) accounts for about 5% of all ALS cases and affects lower motor neurons in the arms, legs, and bulbar region. While PMA is associated with longer survival on average than classical ALS, it is still progressive over time, eventually leading to respiratory failure and death. As with PLS, PMA can also develop into classical ALS over time if the lower motor neuron involvement progresses to include upper motor neurons, in which case the diagnosis might be changed to classic ALS.
Regionally isolated variants Rarely, ALS symptoms may be limited to a single region of the body for an extended period of time. The disease typically progresses more slowly than classical ALS and is associated with longer survival. These regional variants of ALS can only be considered as a diagnosis should the initial symptoms fail to spread to other spinal cord regions for at least 12 months. Flail arm syndrome is characterized by lower motor neuron damage affecting the arm muscles, typically starting with the upper arms symmetrically and progressing downwards to the hands. Flail leg syndrome is characterized by lower motor neuron damage leading to asymmetrical weakness and wasting in the legs starting around the feet. Isolated bulbar palsy is characterized by upper or lower motor neuron damage in the bulbar region (in the absence of limb symptoms for at least 20 months), leading to gradual onset of difficulty with speech (dysarthria) and swallowing (dysphagia).
Age of onset ALS can also be classified based on the age of onset. People with familial ALS have an age of onset about 5 years younger than those with apparently sporadic ALS. About 10% of all cases of ALS begin before age 45 ("young-onset" ALS), and about 1% of all cases begin before age 25 ("juvenile" ALS). People who develop young-onset ALS are more likely to be male, less likely to have bulbar onset of symptoms, and more likely to have a slower progression of the disease. Juvenile ALS is more likely to be genetic in origin than adult-onset ALS; the most common genes associated with juvenile ALS are FUS, ALS2, and SETX. Although most people with juvenile ALS live longer than those with adult-onset ALS, some of them have specific mutations in FUS and SOD1 that are associated with a poor prognosis. Late onset (after age 65) is generally associated with a more rapid functional decline and shorter survival.
Signs and symptoms The disorder causes muscle weakness, atrophy, and muscle spasms throughout the body due to the degeneration of the upper motor and lower motor neurons. Sensory nerves and the autonomic nervous system are generally unaffected, meaning the majority of people with ALS maintain hearing, sight, touch, smell, and taste.
Initial symptoms Early signs of ALS may be so subtle that the symptoms are overlooked. The earliest symptoms of ALS are muscle weakness or muscle atrophy, typically on one side of the body. Other presenting symptoms include trouble swallowing or breathing, cramping, or stiffness of affected muscles; muscle weakness affecting an arm or a leg; or slurred and nasal speech. The parts of the body affected by early symptoms of ALS depend on which motor neurons in the body are damaged first. In limb-onset ALS, the first symptoms are in the arms or the legs. If the legs are affected first, people may experience awkwardness, tripping, or stumbling when walking or running; this is often marked by walking with a "dropped foot" that drags gently on the ground. If the arms are affected first, they may experience difficulty with tasks requiring manual dexterity, such as buttoning a shirt, writing, or turning a key in a lock. In bulbar-onset ALS, the first symptoms are difficulty speaking or swallowing. Speech may become slurred, nasal in character, or quieter. There may be difficulty with swallowing and loss of tongue mobility. A smaller proportion of people experience "respiratory-onset" ALS, where the intercostal muscles that support breathing are affected first. Over time, people experience increasing difficulty moving, swallowing (dysphagia), and speaking or forming words (dysarthria). Symptoms of upper motor neuron involvement include tight and stiff muscles (spasticity) and exaggerated reflexes (hyperreflexia), including an overactive gag reflex. While the disease does not cause pain directly, pain is a symptom experienced by most people with ALS, caused by reduced mobility, and possibly also some sensory nerve dysfunction. Symptoms of lower motor neuron degeneration include muscle weakness and atrophy, muscle cramps, and fleeting twitches of muscles that can be seen under the skin (fasciculations).
Progression Although the initial site of symptoms and subsequent rate of disability progression vary from person to person, the initially affected body region is usually the most affected over time, and symptoms usually spread to a neighbouring body region. For example, symptoms starting in one arm usually spread to either the opposite arm or to the leg on the same side. Bulbar-onset patients most typically experience their next symptoms in their arms rather than legs, arm-onset patients typically spread to the legs before the bulbar region, and leg-onset patients typically spread to the arms rather than the bulbar region. Over time, regardless of where symptoms began, most people eventually lose the ability to walk or use their hands and arms independently. They may also lose the ability to speak and to swallow food. It is the eventual development of weakness of the respiratory muscles, with the loss of ability to cough and to breathe without mechanical support, that is ultimately life-shortening in ALS. The rate of progression can be measured using the ALS Functional Rating Scale - Revised (ALSFRS-R), a 12-item instrument survey administered as a clinical interview or self-reported questionnaire that produces a score between 48 (normal function) and 0 (severe disability). The ALSFRS-R is the most frequently used outcome measure in clinical trials and is used by doctors to track disease progression. On average, people with ALS lose about 1 ALSFRS-R point per month. Brief periods of stabilization ("plateaus") and even small reversals in ALSFRS-R score are not uncommon, owing to the subjective nature of scoring, effects of symptomatic medication, and patients' own compensations for changes in function. However, it is rare (<1%) for these improvements to be large (i.e. greater than 4 ALSFRS-R points) or sustained (i.e. greater than 12 months). A survey-based study among clinicians showed that they rated a 20% change in the slope of the ALSFRS-R as being clinically meaningful, hence its common usage as a threshold to determine efficacy of new treatments in clinical trials.
Late-stage disease management Difficulties with chewing and swallowing make eating very difficult (dysphagia) and increase the risk of choking or of aspirating food into the lungs. In later stages of the disorder, aspiration pneumonia can develop, and maintaining a healthy weight can become a significant problem that may require the insertion of a feeding tube. As the diaphragm and intercostal muscles of the rib cage that support breathing weaken, measures of lung function such as vital capacity and inspiratory pressure diminish. In respiratory-onset ALS, this may occur before significant limb weakness is apparent. Individuals affected by the disorder may ultimately lose the ability to initiate and control all voluntary movement, known as locked-in syndrome. Bladder and bowel function are usually spared, meaning urinary and fecal incontinence are uncommon, although trouble getting to a toilet can lead to difficulties. The extraocular muscles responsible for eye movement are usually spared, meaning the use of eye tracking technology to support augmentative communication is often feasible. Despite these challenges, many people in an advanced state of disease report satisfactory well-being and quality of life with these supportive measures.
Prognosis, staging, and survival Although respiratory support using non-invasive ventilation can ease problems with breathing and prolong survival, it does not affect the progression rate of ALS. Most people with ALS die between two and four years after the diagnosis. About 50% of people with ALS die within 30 months of their symptoms beginning, about 20% live between five and ten years, and about 10% survive for 10 years or longer. The most common cause of death among people with ALS is respiratory failure, often accelerated by pneumonia. Most ALS patients die at home after a period of worsening difficulty breathing, a decline in their nutritional status, or a rapid worsening of symptoms. Sudden death or acute respiratory distress are uncommon. Access to palliative care is recommended from an early stage to explore options, ensure psychosocial support for the patient and caregivers, and to discuss advance healthcare directives. As with cancer staging, ALS has staging systems numbered between 1 and 4 that are used for research purposes in clinical trials. Two very similar staging systems emerged around a similar time: the King's staging system and Milano-Torino (MiToS) functional staging.
Providing individual patients with a precise prognosis is not currently possible, though research is underway to provide statistical models on the basis of prognostic factors, including age at onset, progression rate, site of onset, and presence of frontotemporal dementia. Bulbar-onset ALS typically has a worse prognosis than limb-onset ALS; a population-based study found that bulbar-onset ALS patients had a median survival of 2.0 years and a 10-year survival rate of 3%, while limb-onset ALS patients had a median survival of 2.6 years and a 10-year survival rate of 13%. Those with respiratory-onset ALS had a shorter median survival of 1.4 years and 0% survival at 10 years. Though notable astrophysicist Stephen Hawking lived for 55 more years following his diagnosis, his case was an unusual one.
Cognitive, emotional, and behavioral symptoms Cognitive impairment or behavioral dysfunction is present in 30–50% of individuals with ALS, and can appear more frequently in later stages of the disease. Language dysfunction, executive dysfunction, and troubles with social cognition and verbal memory are the most commonly reported cognitive symptoms in ALS. Cognitive impairment is found more frequently in patients with C9orf72 gene repeat expansions, bulbar onset, bulbar symptoms, family history of ALS and/or a predominantly upper motor neuron phenotype. Pseudobulbar affect and emotional lability are a type of symptom in which patients cry, smile, yawn, or laugh, either in the absence of emotional stimuli, or when they are feeling the opposite emotion to that being expressed. Approximately half of ALS patients experience this; it is more common in those with bulbar-onset ALS. While more or less benign relative to other symptoms, it can cause increased stigma and social isolation as people around the patient struggle to react appropriately to what can be frequent and inappropriate outbursts in public. In addition to mild changes in cognition that may only emerge during neuropsychological testing, around 10–15% of individuals have signs of frontotemporal dementia (FTD). Repeating phrases or gestures, apathy, and loss of inhibition are the most frequently reported behavioral features of ALS. ALS and FTD are now considered to be part of a common disease spectrum (ALS–FTD) because of genetic, clinical, and pathological similarities. Cognitive and behavioral issues are associated with a poorer prognosis as they may reduce adherence to medical advice and deficits in empathy and social cognition, which may increase caregiver burden.
Cause Sporadic ALS has no known cause and is described as an idiopathic disease. Though its exact cause is unknown, genetic and environmental factors are thought to be of roughly equal importance. The genetic factors are better understood than the environmental factors; no specific environmental factor has been definitively shown to cause ALS. A multi-step liability threshold model for ALS proposes that cellular damage accumulates over time due to genetic factors present at birth and exposure to environmental risks throughout life. ALS can strike at any age, but its likelihood increases with age. Most people who develop ALS are between the ages of 40 and 70, with an average age of 55 at the time of diagnosis. ALS is 20% more common in men than women, but this difference in sex distribution is no longer present in patients with onset after age 70.
Genetics and genetic testing
ALS can be classified as either familial or sporadic, depending on whether there is a known family history of the disease and/or whether an ALS-associated genetic mutation has been identified via genetic testing. Familial ALS is thought to account for 10–15% of cases overall and can include monogenic, oligogenic, and polygenic modes of inheritance. There is considerable variation among clinicians on whether to conduct genetic testing in ALS, particularly if there is no discernible family history of the disease. In the past, genetic counseling and testing was only offered to those with obviously familial ALS. It is increasingly recognized that cases of sporadic ALS may also be due to disease-causing de novo mutations in SOD1, or C9orf72, or inherited mutations which were overlooked due to incomplete family history or incomplete penetrance. The lack of positive family history may be caused by lack of historical records, having a smaller family, older generations dying earlier of causes other than ALS, genetic non-paternity, and uncertainty over whether certain neuropsychiatric conditions (e.g. frontotemporal dementia, other forms of dementia, suicide, psychosis, schizophrenia) should be considered significant when determining a family history. There have been calls in the research community to routinely counsel and test all diagnosed ALS patients for familial ALS, especially due to the availability of genetic medicine (tofersen) for carriers of SOD1 ALS. A shortage of genetic counselors and limited clinical capacity to see such at-risk individuals make this challenging in practice, as does the unequal access to genetic testing around the world. More than 40 genes have been associated with ALS, of which four account for nearly half of familial cases, and around 5% of sporadic cases: C9orf72 (40% of familial cases, 7% sporadic), SOD1 (12% of familial cases, 1–2% sporadic), FUS (4% of familial cases, 1% sporadic), and TARDBP (4% of familial cases, 1% sporadic), with the remaining genes mostly accounting for fewer than 1% of either familial or sporadic cases. Notably, repeat expansions in the C9orf72 gene account for about 40% of genetic ALS and 25% of genetic FTD, leading to the redefinition of ALS and FTD as lying on a shared disease spectrum. ALS genes identified to date explain the cause of about 70% of familial ALS and about 15% of sporadic ALS. Overall, first-degree relatives of an individual with ALS have a ~1% risk of developing ALS themselves. SOD (superoxide dismutase) refers to a group of enzymes that target and reduce the presence of harmful reactive oxygen species (ROS) to protect cells. Subsequently, SOD enzymes are often critical in ensuring appropriate conditions for neuronal/neural pathway development. SOD1, a subspecies within the main SOD gene family, is a metalloenzyme characterized by the two main metal groups it contains—Zinc (Zn) and Copper (Cu). The Cu-Zn superoxide dismutase metabolizes superoxide radicals to oxygen and hydrogen peroxide, defending organisms against oxygen toxicity. Various gene inhibition and knockdown experiments in model organisms such as Drosophila melanogaster have indicated the key role of SOD enzyme activity in neuronal remodeling. SOD gene mutation has been linked to inhibited motor function and ability, as well as a decreased capacity for affected organisms to function and perform physical behaviors normally due to dysfunctional movement and muscle degeneration. These downregulated transcripts are responsible for mediating axon extension and guidance functions; mutations in SOD1 genes are linked with neuronal defects/neuroinflammation similar to the symptoms of ALS.
Environmental and other factors The multi-step hypothesis suggests the disease is caused by some interaction between an individual's genetic risk factors and their cumulative lifetime of exposures to environmental factors, termed their exposome. The most consistent lifetime exposures associated with developing ALS (other than genetic mutations) include heavy metals (e.g. lead and mercury), chemicals (e.g. pesticides and solvents), electric shock, physical injury (including head injury), and smoking (in men more than women). Generally, the effect of each exposure is relatively small. For instance, an individual's lifetime risk of developing ALS might increase from "1 in 400" without exposure to between "1 in 300" and "1 in 200" if they were exposed to heavy metals. Some industries are heavily dependent upon the use or exposure to these environmental factors, which may increase employees' susceptibility. For example, agricultural tasks may involve as many as 5 such risk factors excluding workers' smoking habits. A range of other factors have weaker evidence supporting them and include participation in professional sports, having a lower body mass index, lower educational attainment, manual occupations, military service, exposure to beta-Methylamino-L-alanine (BMAA), and viral infections. Although some personality traits, such as openness, agreeableness and conscientiousness appear remarkably common among patients with ALS, it remains open whether personality can increase susceptibility to ALS directly. Instead, genetic factors giving rise to personality might simultaneously predispose people to develop ALS, or the above personality traits might underlie lifestyle choices which are in turn risk factors for ALS.
Viruses and retrotransposons Many ALS patients have substantially increased expression of endogenous retroviruses (HERVs), which are remnants of infections that may have happened early in human evolution and remained integrated in the human genome. Similarly, about one in five people with ALS had high levels of retrotransposon activation and dysfunction of TDP-43, a protein which regulates human gene expression and inhibits activation of retroviral genes. Preliminary data suggest that antiviral therapy may be used to treat ALS and related diseases.
Autoimmune processes Multiple studies have provided evidence suggesting that motor neurons in ALS patients may be susceptible to inflammatory responses driven by autoreactive immune cells. In 1991, researchers with Baylor College of Medicine found that antibodies could be used to target motor neurons in a mouse model, leading to limb weakness and other symptoms similar to ALS symptoms in humans. In 2025, researchers at Columbia University Medical School and La Jolla Institute for Immunology published the first study showing inflammatory T cells targeting a specific antigen (vulnerable site) on motor neurons in patients with ALS.
Pathophysiology
Neuropathology Upon examination at autopsy, features of the disease that can be seen with the naked eye include skeletal muscle atrophy, motor cortex atrophy, sclerosis of the corticospinal and corticobulbar tracts, thinning of the hypoglossal nerves (which control the tongue), and thinning of the anterior roots of the spinal cord. The defining feature of ALS is the death of both upper motor neurons (located in the motor cortex of the brain) and lower motor neurons (located in the brainstem and spinal cord). In ALS with frontotemporal dementia, neurons throughout the frontal and temporal lobes of the brain die as well. The pathological hallmark of ALS is the presence of inclusion bodies (abnormal aggregations of protein) known as Bunina bodies in the cytoplasm of motor neurons. In about 97% of people with ALS, the main component of the inclusion bodies is TDP-43 protein; however, in those with SOD1 or FUS mutations, the main component of the inclusion bodies is SOD1 or FUS protein, respectively. Prion-like propagation of misfolded proteins from cell to cell may explain why ALS starts in one area and spreads to others. The glymphatic system may also be involved in the pathogenesis of ALS.
Biochemistry
Neurodegeneration in ALS is thought to involve many different cellular and molecular processes. The genes known to be involved in ALS can be grouped into three general categories based on their normal function: protein degradation, the cytoskeleton, and RNA processing. Mutant SOD1 protein forms intracellular aggregations that inhibit protein degradation. Cytoplasmic aggregations of wild-type (normal) SOD1 protein are common in sporadic ALS. It is thought that misfolded mutant SOD1 can cause misfolding and aggregation of wild-type SOD1 in neighboring neurons in a prion-like manner. Other protein degradation genes that can cause ALS when mutated include VCP, OPTN, TBK1, and SQSTM1. Three genes implicated in ALS that are important for cytoskeletal maintenance and axonal transport include DCTN1, PFN1, and TUBA4A. Several ALS genes encode RNA-binding proteins. The first to be discovered was TDP-43 protein, a nuclear protein that aggregates in the cytoplasm of motor neurons in almost all cases of ALS; however, mutations in TARDBP, the gene that codes for TDP-43, are a rare cause of ALS. FUS codes for FUS, another RNA-binding protein with a similar function to TDP-43, which can cause ALS when mutated. It is thought that mutations in TARDBP and FUS increase the binding affinity of the low-complexity domain, causing their respective proteins to aggregate in the cytoplasm. Once these mutant RNA-binding proteins are misfolded and aggregated, they may be able to misfold normal proteins both within and between cells in a prion-like manner. This also leads to decreased levels of RNA-binding protein in the nucleus, which may mean that their target RNA transcripts do not undergo normal processing. Other RNA metabolism genes associated with ALS include ANG, SETX, and MATR3. C9orf72 is the most commonly mutated gene in ALS and causes motor neuron death through several mechanisms. The pathogenic mutation is a hexanucleotide repeat expansion (a series of six nucleotides repeated over and over); people with up to 30 repeats are considered normal, while people with hundreds or thousands of repeats can have familial ALS, frontotemporal dementia, or sometimes sporadic ALS. The three mechanisms of disease associated with these C9orf72 repeats are deposition of RNA transcripts in the nucleus, translation of the RNA into toxic dipeptide repeat proteins in the cytoplasm, and decreased levels of the normal C9orf72 protein. Mitochondrial bioenergetic dysfunction leading to dysfunctional motor neuron axonal homeostasis (reduced axonal length and fast axonal transport of mitochondrial cargo) has been shown to occur in C9orf72-ALS using human induced pluripotent stem cell (iPSC) technologies coupled with CRISPR/Cas9 gene-editing, and human post-mortem spinal cord tissue examination. Excitotoxicity, or nerve cell death caused by high levels of intracellular calcium due to excessive stimulation by the excitatory neurotransmitter glutamate, is a mechanism thought to be common to all forms of ALS. Motor neurons are more sensitive to excitotoxicity than other types of neurons because they have a lower calcium-buffering capacity and a type of glutamate receptor (the AMPA receptor) that is more permeable to calcium. In ALS, there are decreased levels of excitatory amino acid transporter 2 (EAAT2), which is the main transporter that removes glutamate from the synapse; this leads to increased synaptic glutamate levels and excitotoxicity. Riluzole, a drug that modestly prolongs survival in ALS, inhibits glutamate release from presynaptic neurons. However, it is unclear if this mechanism is responsible for its therapeutic effect.
Diagnosis
No single test can provide a definite diagnosis of ALS. Instead, the diagnosis of ALS is primarily made based on a physician's clinical assessment after ruling out other diseases. Physicians often obtain the person's full medical history and conduct neurologic examinations at regular intervals to assess whether signs and symptoms such as muscle weakness, muscle atrophy, hyperreflexia, Babinski's sign, and spasticity are worsening. Many biomarkers are being studied for the condition, but as of 2023 are not in general medical use. In the U.S., average time from first symptom to ALS diagnosis confirmation ranges from 11.5 to 15 months. Even though people with ALS may see 3-4 clinicians prior to referral to an ALS specialist for diagnosis confirmation, the bulk of the diagnostic delay in the U.S. may be while under the care of neurologist(s), particularly non-neuromuscular trained neurologists. The ALS Association assembled a "Time to Diagnosis" (T2D) workgroup composed of ALS specialists, pharmaceutical industry experts, and people with ALS to focus on developing solutions to reduce diagnostic delays. The T2D group developed and published the thinkALS tool, a clinical and referral instrument to increase confidence of early recognition of common ALS clinical features and streamlining referral processes to specialty ALS centers.
Differential diagnosis Because symptoms of ALS can be similar to those of a wide variety of other diseases or disorders, appropriate tests must be conducted to exclude the possibility of other conditions. One of these tests is electromyography (EMG), a special recording technique that detects electrical activity in muscles. Certain EMG findings can support the diagnosis of ALS. Another common test measures nerve conduction velocity (NCV). Specific abnormalities in the NCV results may suggest, for example, that the person has a form of peripheral neuropathy (damage to peripheral nerves) or myopathy (muscle disease) rather than ALS. While a magnetic resonance imaging (MRI) is often normal in people with early-stage ALS, it can reveal evidence of other problems that may be causing the symptoms, such as a spinal cord tumor, multiple sclerosis, a herniated disc in the neck, syringomyelia, or cervical spondylosis. Based on the person's symptoms and findings from these tests, the physician may order tests on blood and urine samples to eliminate the possibility of other diseases, as well as routine laboratory tests. In some cases, for example, if a physician suspects the person may have a myopathy rather than ALS, a muscle biopsy may be performed. Several infectious diseases can sometimes cause ALS-like symptoms, including human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), Lyme disease, and syphilis. Neurological disorders such as multiple sclerosis, post-polio syndrome, multifocal motor neuropathy, CIDP, spinal muscular atrophy, and spinal and bulbar muscular atrophy can also mimic certain aspects of the disease and should be considered. ALS must be differentiated from the "ALS mimic syndromes", which are unrelated disorders that may have a similar presentation and clinical features to ALS or its variants. Because the prognosis of ALS and closely related subtypes of motor neuron disease is generally poor, neurologists may carry out investigations to evaluate and exclude other diagnostic possibilities. Disorders of the neuromuscular junction, such as myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome, may also mimic ALS, although this rarely presents diagnostic difficulty over time. Benign fasciculation syndrome and cramp fasciculation syndrome may also occasionally mimic some of the early symptoms of ALS. Nonetheless, the absence of other neurological features that develop inexorably with ALS means that, over time, the distinction will not present any difficulty to the experienced neurologist; where doubt remains, EMG may be helpful.
Management There is no known cure for ALS. Management focuses on treating symptoms and providing supportive care to improve quality of life and prolong survival. This care is best provided by multidisciplinary teams of healthcare professionals; attending a multidisciplinary ALS clinic is associated with longer survival, fewer hospitalizations, and improved quality of life. Non-invasive ventilation (NIV) is the main treatment for respiratory failure in ALS. In people with normal bulbar function, it prolongs survival by at least several months and improves the quality of life. One study found that NIV is ineffective for people with poor bulbar function while another suggested that it may provide a modest survival benefit. Many people with ALS have had difficulty tolerating NIV; however, more recently, with a larger array of masks from which to choose and the wider availability of volume-control modes and NIV synchronization features that allow for more natural breathing, NIV efficacy and tolerability have improved significantly. Invasive ventilation is an option for people with advanced ALS when NIV is not enough to manage their symptoms. Though invasive ventilation prolongs survival, disease progression, and functional decline continue. It may decrease the quality of life of people with ALS or their caregivers. Invasive ventilation is more commonly used in Japan than in North America or Europe.
Physical therapy can promote functional independence through aerobic, range of motion, and stretching exercises. Occupational therapy can assist with activities of daily living through adaptive equipment. Speech therapy can assist people with ALS who have difficulty speaking. Preventing weight loss and malnutrition in people with ALS improves both survival and quality of life. Initially, difficulty swallowing (dysphagia) can be managed by dietary changes and swallowing techniques. A feeding tube should be considered if someone with ALS loses 5% or more of their body weight or if they cannot safely swallow food and water. The feeding tube is usually inserted by percutaneous endoscopic gastrostomy (PEG). There is weak evidence that PEG tubes improve survival. PEG insertion is usually performed with the intent of improving quality of life. Palliative care should begin shortly after someone is diagnosed with ALS. Discussion of end-of-life issues gives people with ALS time to reflect on their preferences for end-of-life care and can help avoid unwanted interventions or procedures. Hospice care can improve symptom management at the end of life and increase the likelihood of a peaceful death. In the final days of life, opioids can be used to treat pain and dyspnea, while benzodiazepines can be used to treat anxiety.
Medications
Disease-slowing treatments
Riluzole has been found to modestly prolong survival by about 2–3 months. It may have a greater survival benefit for those with bulbar-onset ALS. It may work by decreasing release of the excitatory neurotransmitter glutamate from pre-synaptic neurons. The most common side effects are nausea and a lack of energy (asthenia). People with ALS should begin treatment with riluzole as soon as possible following their diagnosis. Riluzole is available as a tablet, liquid, or dissolvable oral film. Edaravone has been shown to modestly slow the decline in function in a small group of people with early-stage ALS. It may work by protecting motor neurons from oxidative stress. The most common side effects are bruising and gait disturbance. Edaravone is available as an intravenous infusion or as an oral suspension. Tofersen (Qalsody) is an antisense oligonucleotide that was approved for medical use in the United States in April 2023 for the treatment of SOD1-associated ALS. In a study of 108 patients with SOD1-associated ALS there was a non-significant trend towards a slowing of progression, as well as a significant reduction in neurofilament light chain, a putative ALS biomarker thought to indicate neuronal damage. A follow-up study and open-label extension suggested that earlier treatment initiation had a beneficial effect on slowing disease progression. Tofersen is available as an intrathecal injection into the lumbar cistern at the base of the spine. Several gene-targeted therapies are currently under clinical investigation for ALS. Ulefnersen (ION363), an investigational drug designed to suppress the production of toxic mutant FUS protein, is the furthest along and is completing a global Phase 3 trial for FUS-associated ALS in the second half of 2026. Therapies addressing UNC13A mis-splicing are in earlier stages of development, with candidates like QRL-201 showing encouraging safety and biomarker trends in Phase 1/2 proof-of-concept trials ahead of planned Phase 3 evaluation.
Symptomatic treatments Other medications may be used to help reduce fatigue, ease muscle cramps, control spasticity, and reduce excess saliva and phlegm. Gabapentin, pregabalin, and tricyclic antidepressants (e.g., amitriptyline) can be used for neuropathic pain, while nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids can be used for nociceptive pain. Depression can be treated with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, while benzodiazepines can be used for anxiety. There are no medications to treat cognitive impairment/frontotemporal dementia (FTD); however, SSRIs and antipsychotics can help treat some of the symptoms of FTD. Pseudobulbar affect can be treated with Nuedexta (dextromethorphan/quinidine), though this relatively new compound is not available in every country. Baclofen and tizanidine are the most commonly used oral drugs for treating spasticity; an intrathecal baclofen pump can be used for severe spasticity, and mexiletine is safe and effective fo